5:45 PM
 | 
Jun 26, 2013
 |  BC Extra  |  Company News

QRxPharma expects delay for MoxDuo review

QRxPharma Ltd. (ASX:QRX; OTCQX:QRXPY) said it expects FDA to delay an upcoming advisory committee meeting and PDUFA date for MoxDuo IR morphine/oxycodone to treat moderate to...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >